Screener
Eli Lilly LLY Acquired in-process research and development expenses
Acquired in-process research and development expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 3,268 | 2,448 | 6,845 | 4,672 |
| Research and development | 3,819 | 3,336 | 7,329 | 6,070 |
| Marketing, selling, and administrative | 3,430 | 2,753 | 6,364 | 5,221 |
| Acquired in-process research and development | 2,776 | 154 | 3,360 | 1,726 |
| Asset impairment, restructuring, and other special charges | 703 | — | 982 | 35 |
| Other–net, (income) expense | (269) | 90 | (204) | 329 |
| 13,727 | 8,781 | 24,676 | 18,053 | |
| Income before income taxes | 9,247 | 6,777 | 18,097 | 10,233 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's acquired in-process research and development expenses?
- Eli Lilly (LLY) reported acquired in-process research and development expenses of $2.78B in Q2 2026.
- What does acquired in-process research and development expenses mean?
- Acquired in-process research and development expenses
Ask your AI about Eli Lilly's acquired in-process research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude